Clinical trial feasibility in oncology research depends on the continued clinical equipoise between the interventions being compared; when one arm of a randomized comparison becomes widely adopted as standard practice before or during enrollment, physicians and patients lose the motivation to accept randomization, undermining recruitment regardless of the trial's funding or design. This illustrates a general principle in the design and governance of large randomized controlled trials: external adoption trends in medical practice can erode a trial's premise faster than the trial itself can execute, creating a feasibility and relevance problem that formal review mechanisms (institutional advisory boards) must periodically reassess.
Clinical trial feasibility in oncology research depends on the continued clinical equipoise between the interventions being compared; when one arm of a randomized comparison becomes widely adopted as…